Ponatinib active in CML, ph+ acute lymphoblastic leukemia

Ponatinib active in CML, ph+ acute lymphoblastic leukemia

(HealthDay)—Ponatinib is active in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), according to a study published online Nov. 1 in the New England Journal of Medicine.

Jorge E. Cortes, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a phase 2 trial of ponatinib (45 mg once daily) in 449 heavily pretreated with CML or Ph-positive ALL with resistance to or unacceptable side effects from dasatinib or nilotinib, or with the BCR-ABL T315I mutation. Patients were followed for a median of 15 months.

The researchers found that of the 267 patients with chronic-phase CML, 56, 46, and 34 percent, respectively, had a major cytogenetic response, a complete cytogenetic response, and a major molecular response. Responses were durable (estimated rate of sustained major cytogenetic response of at least 12 months, 91 percent) and were seen regardless of the baseline BCR-ABL kinase domain mutation status. Among 83 patients with accelerated-phase CML, 55 and 39 percent, respectively, had a major hematologic and major cytogenetic response, while among the 62 patients with blast phase CML, the response rates were 31 and 23 percent, respectively. The major hematologic and cytogenetic response rates were 41 and 47 percent, respectively, for those with Ph-positive ALL.

"In conclusion, ponatinib showed clinically significant activity in patients with CML and those with Ph-positive ALL," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Ariad Pharmaceuticals, which manufactures ponatinib and funded the study.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Options increase for CML patients failed by existing drugs

Dec 21, 2012

The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved ...

Clinical trial delivers good results in leukemia patients

Nov 30, 2012

Huntsman Cancer Institute (HCI) researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard ...

Recommended for you

Early hormone therapy may be safe for women's hearts

4 hours ago

(HealthDay)—Healthy women at low risk of cardiovascular disease may be able to take hormone replacement therapy soon after menopause for a short time without harming their hearts, according to a new study.

Low yield for repeat colonoscopy in some patients

5 hours ago

(HealthDay)—Repeat colonoscopies within 10 years are of little benefit to patients who had no polyps found on adequate examination; however, repeat colonoscopies do benefit patients when the baseline examination was compromised, ...

Cell's recycling center implicated in division decisions

7 hours ago

Most cells do not divide unless there is enough oxygen present to support their offspring, but certain cancer cells and other cell types circumvent this rule. Researchers at The Johns Hopkins University have now identified ...

User comments